NDC 61703-343

Mitoxantrone

Mitoxantrone

Mitoxantrone is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Hospira, Inc.. The primary component is Mitoxantrone Hy.

Product ID61703-343_17c18d16-76a7-447d-bbcd-7ad7ca4b0787
NDC61703-343
Product TypeHuman Prescription Drug
Proprietary NameMitoxantrone
Generic NameMitoxantrone
Dosage FormInjection, Solution, Concentrate
Route of AdministrationINTRAVENOUS
Marketing Start Date2006-04-11
Marketing CategoryANDA / ANDA
Application NumberANDA076871
Labeler NameHospira, Inc.
Substance NameMITOXANTRONE HY
Active Ingredient Strength2 mg/mL
Pharm ClassesTopoisomerase I
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 61703-343-18

1 VIAL, MULTI-DOSE in 1 CARTON (61703-343-18) > 10 mL in 1 VIAL, MULTI-DOSE
Marketing Start Date2006-04-11
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 61703-343-65 [61703034365]

Mitoxantrone INJECTION, SOLUTION, CONCENTRATE
Marketing CategoryANDA
Application NumberANDA076871
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2006-04-11

NDC 61703-343-66 [61703034366]

Mitoxantrone INJECTION, SOLUTION, CONCENTRATE
Marketing CategoryANDA
Application NumberANDA076871
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2006-04-11

NDC 61703-343-18 [61703034318]

Mitoxantrone INJECTION, SOLUTION, CONCENTRATE
Marketing CategoryANDA
Application NumberANDA076871
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2006-04-11

Drug Details

Pharmacological Class

  • Topoisomerase Inhibitor [EPC]
  • Topoisomerase Inhibitors [MoA]

NDC Crossover Matching brand name "Mitoxantrone" or generic name "Mitoxantrone"

NDCBrand NameGeneric Name
0703-4680mitoXANTRONEmitoXANTRONE
0703-4685mitoXANTRONEmitoXANTRONE
0703-4686mitoXANTRONEmitoXANTRONE
61703-343MitoxantroneMitoxantrone
63323-132MitoxantroneMITOXANTRONE HYDROCHLORIDE

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.